Across pharmaceuticals, medical devices and healthcare, Asia is becoming critically important to Life Sciences supply and demand. Rising middle class incomes and aging populations are fueling domestic markets. Government-led reforms and regulations are promoting greater confidence in product quality. And the region is a hotbed for startups, in part due to its lively incubator scene.
With a rapidly changing value chain and booming healthcare market, Asia is fast becoming central to the global Life Sciences industry.
Navigating this complex market is not easy, however. The rapid pace of change means that even the most experienced company can take a wrong turn. Expert, on-the-ground advice is necessary to keep up with legal and regulatory changes, as well as to find the right location in terms of talent pool, infrastructure and incentives to locate regional headquarters, manufacturing plants or R&D centers.
This is why we have launched "Doing business for Life Sciences companies in Asia". On the back of our successful and long-standing Site Selection for Life Sciences Companies in Europe series, we address latest developments in the larger, emerging Asian markets of China, India, Hong Kong SAR, Singapore, Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
We also take a look at hot topics such as the IPO landscape, healthcare digitalization, and a comparison of the clinical trial application environments in China and the EU. So that you have a study that encompasses the most relevant aspects of deciding on a new location for your business to take advantage of the opportunities – and to mitigate some of the challenges – of expanding in this dynamic region.